Why the study?
Does withholding anticoagulant therapy in 'good risk' myocardial infarction patients lead to thromboembolic complications?
Does withholding anticoagulant therapy in 'good risk' myocardial infarction patients lead to thromboembolic complications?
Even 'good risk' patients with myocardial infarction can develop severe thromboembolic complications, supporting the use of anticoagulant therapy unless contraindicated.
Answers are grounded in this paper and cite their sources.
Thromboembolic complications arose in 'good risk' MI without anticoagulation; hypothesis-generating and should not yet change practice.
Thromboembolic complications frequently occur following myocardial infarction. Following the general acceptance of anticoagulant therapy for the treatment of myocardial infarction, there have been some authors who have recommended that this therapy be withheld from "mild cases," unless they develop thromboembolic complications. It is the belief of the present authors that this is not justified unless there are contraindications for anticoagulant treatment, provided that proper facilities are available. Summaries of experience with 14 so-called "good risk" cases of myocardial infarction who developed a total of 18 certain and 4 probable thromboembolic complications are presented. As a result, there were 4 major amputations in 3 patients, 1 of whom died. Other complications are discussed in detail.
No takes yet. Share an insight, caveat, or question.
Francisco et al. (1956) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: